Nephrotic syndrome: vizsgálatok itt: Lengyelország
5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Where
- Lodz, Opole, Poznan
- Életkor
- 16 év to 75 év
- People
- 84 worldwide
- Run by
- Sanofi
See details and how to joinNCT06500702 - 3. fázisTaking peopleBOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults. (B cell Depletion Therapy to Improve Outcomes of Relapsing STERoid-sensitive Podocytopathies in Adults – BOOSTER trial)
- Where
- Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Olsztyn, Opole, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 70
- Run by
- Medical University Of Lodz
See details and how to join2023-509755-13-00 - 2. fázisTaking peopleStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Where
- Cracow
- Életkor
- 1 év to 17 év
- People
- 67 worldwide
- Run by
- Travere Therapeutics, Inc.
See details and how to joinNCT05003986 · EU 2023-505497-14-00 - 3. fázisTaking peopleEarly rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome
- Where
- Bialystok, Gdansk, Krakow, Lodz, Lublin, Poznań, Warszawa, Wrocław, Zabrze
- Életkor
- Up to 17 év
- People
- 60
- Run by
- Medical University Of Gdansk
See details and how to join2024-515058-26-00 - 3. fázisTaking peopleKetoanalogues for Muscle Mass Loss in Nephrotic Syndrome
- Where
- Cracow, Gdansk, Grodzisk Mazowiecki, Lodz, Radom, Rzeszów, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 150
- Run by
- Military Institute od Medicine National Research Institute
See details and how to joinNCT05716880 · EU 2024-517880-22-00